Tag: Press Release

Artificial Intelligence: Revolutionizing Precision Oncology

August 27, 2024

“Properly leveraged AI-based techniques could herald a new era of precision medicine guided by non-invasive, imaging-based disease evaluation." BUFFALO, NY- August 27, 2024 – A new editorial was published in… read more

Oncotarget

Genotype Matters: Tailored Screening for Germline CHEK2 Variants

August 26, 2024

“In our study, we postulated that these differences were driven by three common low-risk (LR) missense variants: p.I157T, p.S428F, and p.T476M, all of which have a BC odds ratio of… read more

Oncotarget

Disrupting NKG2A:HLA-E Interactions for Enhanced Anti-Cancer Immunity

August 21, 2024

“[...] there is strong preclinical evidence that disruption of NKG2A interactions with HLA-E can stimulate both NK cell and cytotoxic T cell effector functions against cancer.” BUFFALO, NY- August 21,… read more

Oncotarget

Role of the Gut Barrier in Colorectal Cancer Treatment

August 19, 2024

“Herein we discuss how gut microbiota and microbial metabolites regulate basal inflammation levels in the gut and the healing process of the bowel after surgery.” BUFFALO, NY- August 19, 2024… read more

Oncotarget

Nanobody Inhibits Metastasis of Breast Tumor Cells to Lung in Mice

August 15, 2024

“In the present study we describe the development of an inhibitory nanobody directed against an extracellular epitope present in the native V-ATPase c subunit.” BUFFALO, NY- August 15, 2024 –… read more

Oncotarget

Response of BRAF-Mutated Spindle Cell Sarcoma to BRAF/MEK Inhibitors

August 14, 2024

“This is the first report of spindle cell sarcoma BRAF V600E/S607T double-mutated, responding to a combination of B-Raf and MEK inhibitors.” BUFFALO, NY- August 14, 2024 – A new case… read more

Targeting the multifaceted BRAF in cancer: New directions

Oncotarget

New Directions in Targeting the Multifaceted BRAF in Cancer

August 12, 2024

“Here we discuss the diverse forms of BRAF alterations found in human cancers and the strategies to inhibit them in patients harboring cancers of distinct origins.” BUFFALO, NY- August 12,… read more

Chemical complementarity of tumor resident, T-cell receptor CDR3s and renalase-1 correlates with increased melanoma survival

Oncotarget

TCR CDR3s and Renalase-1 Linked to Increased Melanoma Survival

August 8, 2024

“These findings indicate that renalase-1 is a potential antigen for TCR recognition in melanoma and could be considered as a target for immunotherapy.” BUFFALO, NY- August 8, 2024 – A… read more

Oncotarget

Dealing with Runaway Metastatic Disease

August 7, 2024

"Metastatic disease remains a major issue in daily practice in oncology because the outcome is still often fatal.” BUFFALO, NY - August 7, 2024 – A new editorial paper was… read more

INT-1B3, an LNP formulated miR-193a-3p mimic, promotes anti-tumor immunity by enhancing T cell mediated immune responses via modulation of the tumor microenvironment and induction of immunogenic cell death

Oncotarget

INT-1B3 miR-193a-3p Mimic Boosts T Cell Immunity and Induces Tumor Cell Death

August 5, 2024

“INT-1B3 inhibited distant tumor metastasis and significantly prolonged survival.” BUFFALO, NY- August 5, 2024 – A new research paper was published in Oncotarget's Volume 15 on July 12, 2024, entitled,… read more